JP2002539265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002539265A5 JP2002539265A5 JP2000606246A JP2000606246A JP2002539265A5 JP 2002539265 A5 JP2002539265 A5 JP 2002539265A5 JP 2000606246 A JP2000606246 A JP 2000606246A JP 2000606246 A JP2000606246 A JP 2000606246A JP 2002539265 A5 JP2002539265 A5 JP 2002539265A5
- Authority
- JP
- Japan
- Prior art keywords
- antitumor drug
- oligonucleotide
- tumor
- group
- stabilization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 description 18
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000011105 stabilization Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9903433A FR2790955B1 (fr) | 1999-03-19 | 1999-03-19 | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| FR99/03433 | 1999-03-19 | ||
| PCT/FR2000/000676 WO2000056342A2 (fr) | 1999-03-19 | 2000-03-17 | Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002539265A JP2002539265A (ja) | 2002-11-19 |
| JP2002539265A5 true JP2002539265A5 (https=) | 2007-05-17 |
Family
ID=9543401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000606246A Pending JP2002539265A (ja) | 1999-03-19 | 2000-03-17 | 抗腫瘍活性を有する薬剤を製造するための安定化オリゴヌクレオチドの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7700569B1 (https=) |
| EP (1) | EP1162982B9 (https=) |
| JP (1) | JP2002539265A (https=) |
| AT (1) | ATE288759T1 (https=) |
| AU (1) | AU3300600A (https=) |
| CA (1) | CA2371990A1 (https=) |
| DE (1) | DE60018050T2 (https=) |
| DK (1) | DK1162982T3 (https=) |
| ES (1) | ES2235839T3 (https=) |
| FR (1) | FR2790955B1 (https=) |
| PT (1) | PT1162982E (https=) |
| WO (1) | WO2000056342A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2711670B1 (fr) * | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| ES2572834T3 (es) | 1999-02-17 | 2016-06-02 | Csl Limited | Complejos inmunogénicos y métodos relacionados con los mismos |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| ATE411054T1 (de) | 2001-08-17 | 2008-10-15 | Coley Pharm Gmbh | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
| US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| CN1753687A (zh) | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
| US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| CA2502015A1 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5' cpg nucleic acids and methods of use |
| CA2542099A1 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| EP1765361A2 (fr) * | 2004-06-25 | 2007-03-28 | Institut Gustave Roussy | Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant |
| EP1649859A1 (fr) * | 2004-10-22 | 2006-04-26 | Institut Gustave Roussy | Produits pharmaceutiques contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant sous forme d'oligodésoxynucléotide |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| CN101171033A (zh) | 2005-03-04 | 2008-04-30 | 戴纳瓦克斯技术公司 | 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定 |
| US7943591B2 (en) * | 2007-05-11 | 2011-05-17 | Adynxx, Inc. | Gene expression and pain |
| FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| US20130210896A1 (en) * | 2011-11-09 | 2013-08-15 | City Of Hope | Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System |
| PT2846839T (pt) | 2012-05-10 | 2019-05-29 | Adynxx Inc | Formulações para a administração de ingredientes ativos |
| RU2017108238A (ru) | 2014-08-15 | 2018-09-17 | Эйдинкс, Инк. | Олигонуклеотиды-приманки для лечения боли |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| CA3093093A1 (en) | 2018-03-07 | 2019-09-12 | Transgene | Parapoxvirus vectors |
| US20220056481A1 (en) | 2018-12-28 | 2022-02-24 | Transgene | M2-defective poxvirus |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5734033A (en) * | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| EP0468520A3 (en) * | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
| JPH04352724A (ja) * | 1990-07-27 | 1992-12-07 | Mitsui Toatsu Chem Inc | 免疫調節型治療剤 |
| WO1993005182A1 (en) | 1991-09-05 | 1993-03-18 | Isis Pharmaceuticals, Inc. | Determination of oligonucleotides for therapeutics, diagnostics and research reagents |
| US6455689B1 (en) | 1993-04-30 | 2002-09-24 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Antisense-oligonucleotides for transforming growth factor-β (TGF-β) |
| WO1995002051A2 (en) * | 1993-07-10 | 1995-01-19 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms |
| US6001982A (en) | 1993-07-29 | 1999-12-14 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| JP2001505401A (ja) * | 1993-09-20 | 2001-04-24 | シー． リード，ジョン | ｂｃ１−２遺伝子発現の調節 |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1167379A3 (en) * | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
| US6280978B1 (en) * | 1995-12-15 | 2001-08-28 | Intronn Holdings, Llc | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| DE69708878T2 (de) | 1996-05-22 | 2002-07-25 | Mcgill University, Montreal | Spezifische inhibitoren vom dna-methyltransferaseenzym |
| EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| US5965420A (en) * | 1997-03-05 | 1999-10-12 | Smithkline Beecham Corporation | Human protein kinases hYAK3 |
| EP1003850B1 (en) * | 1997-06-06 | 2009-05-27 | The Regents of the University of California | Inhibitors of dna immunostimulatory sequence activity |
| DE69829984D1 (de) | 1997-08-29 | 2005-06-02 | Univ California | Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung |
| JP4663113B2 (ja) * | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用 |
| US5874416A (en) * | 1997-11-07 | 1999-02-23 | Sheikhnejad; Gholamreza | RAS antisense inhibition |
| US6060310A (en) | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
| US6020475A (en) | 1998-02-10 | 2000-02-01 | Isis Pharmeuticals, Inc. | Process for the synthesis of oligomeric compounds |
| AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US6166239A (en) | 1998-09-04 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide protecting groups |
| ATE326239T1 (de) | 1998-09-18 | 2006-06-15 | Dynavax Tech Corp | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
| US6069243A (en) | 1998-10-06 | 2000-05-30 | Isis Pharmaceuticals, Inc. | Process for oligonucleotide synthesis |
| AU6425999A (en) | 1998-10-09 | 2000-05-01 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
| US6169177B1 (en) | 1998-11-06 | 2001-01-02 | Isis Pharmaceuticals, Inc. | Processes for the synthesis of oligomeric compounds |
| US6121437A (en) | 1999-03-16 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Phosphate and thiophosphate protecting groups |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| WO2000062923A1 (en) | 1999-04-19 | 2000-10-26 | Engelhard Corporation | Catalyst composition comprising ceria and a platinum group metal |
| WO2001051061A1 (en) * | 2000-01-14 | 2001-07-19 | Intrabiotics Pharmaceuticals, Inc. | Derivatives of polyene macrolides and preparation and use thereof |
-
1999
- 1999-03-19 FR FR9903433A patent/FR2790955B1/fr not_active Expired - Fee Related
-
2000
- 2000-03-17 DE DE60018050T patent/DE60018050T2/de not_active Expired - Lifetime
- 2000-03-17 JP JP2000606246A patent/JP2002539265A/ja active Pending
- 2000-03-17 CA CA002371990A patent/CA2371990A1/fr not_active Abandoned
- 2000-03-17 DK DK00910993T patent/DK1162982T3/da active
- 2000-03-17 US US09/937,057 patent/US7700569B1/en not_active Expired - Fee Related
- 2000-03-17 WO PCT/FR2000/000676 patent/WO2000056342A2/fr not_active Ceased
- 2000-03-17 ES ES00910993T patent/ES2235839T3/es not_active Expired - Lifetime
- 2000-03-17 AT AT00910993T patent/ATE288759T1/de active
- 2000-03-17 PT PT00910993T patent/PT1162982E/pt unknown
- 2000-03-17 EP EP00910993A patent/EP1162982B9/fr not_active Expired - Lifetime
- 2000-03-17 AU AU33006/00A patent/AU3300600A/en not_active Abandoned
-
2001
- 2001-09-28 US US09/967,881 patent/US7108844B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002539265A5 (https=) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| KR101107818B1 (ko) | 향상된 면역자극 효능을 가진 ｃ-부류 올리고뉴클레오티드유사체 | |
| JP4443810B2 (ja) | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節 | |
| ES2856844T3 (es) | Inmunoterapia antitumoral combinada | |
| ES2235839T3 (es) | Uso de oligonucleotidos estabilizados para la preparacion de un medicamento de accion antitumoral. | |
| US8389495B2 (en) | Olioodeoxynucleotide and its use to induce an immune response | |
| ES2238044T3 (es) | Modulacion de la estimulacion inmunologica mediada por el oligonucleotido cpg mediante modificacion posicional de nucleosidos. | |
| JP2022512975A5 (https=) | ||
| JP2006512927A (ja) | ５’ｃｐｇ核酸およびその使用方法 | |
| JP2002535015A5 (https=) | ||
| CA2288222A1 (en) | Oligonucleotide mediated specific cytokine induction and in vivo protection from infection | |
| JP2007506790A (ja) | 核酸親油性接合体 | |
| CA2520541A1 (en) | Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field | |
| JP2004509970A5 (https=) | ||
| JP2018530529A5 (https=) | ||
| JP2003510290A5 (https=) | ||
| DK0928335T3 (da) | Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider | |
| JP2018520685A5 (https=) | ||
| JP2008531018A5 (https=) | ||
| RU2007101039A (ru) | Иммуностимулирующие олигонуклеотидные мультимеры | |
| JP2006503904A5 (https=) | ||
| JP2001527050A5 (https=) | ||
| JP2006515277A5 (https=) | ||
| GB0025577D0 (en) | Vaccine |